Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Summary

This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.

Timeline

Start

2020-12-07

Primary completion

2025-12-31

Completion

2027-01-02

Outcome

Outcome not reported

Stopped: “Due to a Dose Limiting Toxicity in another sister trial with same technology.”

Drugs

Indications